AstraZeneca and IIDF sign a memorandum of collaboration

| By | AstraZeneca, IIDF

AstraZeneca, an international biopharmaceutical company, and the Internet Initiatives Development Fund (IIDF) signed a Memorandum of Intent to collaborate in the area of digital solutions for the pharmaceutical industry.

As part of their collaboration, AstraZeneca and IIDF plan to elaborate a concept for implementing the digital innovative solutions in the pharmaceutical industry to improve quality and availability of modern treatment methods. The partners also intend to implement joint initiatives aimed at spreading a culture of innovation and new tools to be used both by patients and pharmaceutical market participants. An additional area of joint activities will be support for digital entrepreneurship and technological business solutions (including, big data analytics, augmented reality, and chatbots).

Irina Panarina, the General Director of AstraZeneca Russia & Eurasia, said: “Leadership in science is a strategic priority for AstraZeneca. We are focused on innovation and seeking to introduce new products and medicines for the benefit of patients and health care system in Russia. We are actively developing local partnerships in research and education. Today, we are pleased to announce the beginning of collaboration with IIDF and we are confident that it has a great potential.”

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.